A share price of Xeris Biopharma Holdings Inc [XERS] is currently trading at $7.72, down -6.99%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XERS shares have gain 3.07% over the last week, with a monthly amount glided 1.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler downgraded its rating to Neutral on November 11, 2024, and kept the price target unchanged to $3. On March 28, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $5 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $4.50 on August 28, 2023. Jefferies initiated its recommendation with a Buy and recommended $4 as its price target on October 21, 2022. Craig Hallum started tracking with a Buy rating for this stock on April 28, 2022, and assigned it a price target of $6.50. In a note dated November 17, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
Xeris Biopharma Holdings Inc experienced fluctuations in its stock price throughout the past year between $2.69 and $8.34. Currently, Wall Street analysts expect the stock to reach $5.53 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $7.72 at the most recent close of the market. An investor can expect a potential drop of -28.37% based on the average XERS price forecast.
Analyzing the XERS fundamentals
Trailing Twelve Months sales for Xeris Biopharma Holdings Inc [NASDAQ:XERS] were 246.03M which represents 48.84% growth. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is 1.14 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -13.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xeris Biopharma Holdings Inc [NASDAQ:XERS] is 1.95. Further, the Quick Ratio stands at 1.24, while the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 5.07.
Transactions by insiders
Recent insider trading involved PERSKY MARLA, Director, that happened on Sep 11 ’25 when 15500.0 shares were sold. Director, MARLA PERSKY completed a deal on Sep 11 ’25 to buy 15500.0 shares. Meanwhile, Director SHERMAN JEFFREY W sold 42232.0 shares on Aug 28 ’25.
